News

Filter
Filter

Perthera, Inc. Announces the Appointment of Gary L. Gregory as Chief Executive Officer, President and Board Member

Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.

Perthera, UVA, and EVMS Team to Study the Implementation and Clinical Impact of a Next Generation Precision Oncology Platform for Pancreatic Cancer Patients

McLean, VA // Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

ASCO Daily News: Genomic and Transcriptomic Profiling Finds Potential Predictors and Therapeutic Targets in Pancreatic Cancer

Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.

Perthera and the Pancreatic Cancer Action Network Publish Landmark Precision Medicine Study

Using real-world data from over 640 patients with pancreatic cancer, this landmark study demonstrated a 2.2 fold increase in progression-free survival for those being treated with a molecularly-matched therapy. Attached is a pdf of the press release.

Perthera’s Subha Madhavan, Ph.D., to Speak at Prestigious Health 2.0 Conference

McLean, VA –(PR.com)– Perthera Inc.’s, Subha Madhavan, PhD, Chief Bioinformatics Officer, will be speaking at the 11th Annual Fall Conference of Health 2.0 on Healthcare Innovations, Oct 1 – 4 in Santa Clara, CA, in the Personalized Health Track “Turning Data into Value.”

THIS IS AI-POWERED PRECISION ONCOLOGY

Contact Us